3 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 3 |
Follow TQB2450 injection: new trials by email Literature Review of TQB2450 injection trials Research Report on TQB2450 injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer Anlotinib Hydrochloride Capsules, Paclitaxel injection, TQB2450 injection - Recurrent Platinum-resistant Ovarian Cancer | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 405 | 2021-09-28 | 2021-12-08 |
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection - Non Small Cell Lung Cancer | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 375 | 2021-08-06 | 2021-08-20 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection - Advanced Biliary Cancer | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 392 | 2021-02-04 | 2021-03-22 |
Carcinoma, Non-Small-Cell Lung (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3)
China (3)